| CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer M Griffith, NC Spies, K Krysiak, JF McMichael, AC Coffman, AM Danos, ... Nature genetics 49 (2), 170-174, 2017 | 601 | 2017 |
| Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ... Cell 183 (3), 818-834. e13, 2020 | 433 | 2020 |
| DGIdb 2.0: mining clinically relevant drug–gene interactions AH Wagner, AC Coffman, BJ Ainscough, NC Spies, ZL Skidmore, ... Nucleic acids research 44 (D1), D1036-D1044, 2016 | 410 | 2016 |
| Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma CS Grasso, J Tsoi, M Onyshchenko, G Abril-Rodriguez, ... Cancer cell 38 (4), 500-515. e3, 2020 | 335 | 2020 |
| GenVisR: genomic visualizations in R ZL Skidmore, AH Wagner, R Lesurf, KM Campbell, J Kunisaki, OL Griffith, ... Bioinformatics 32 (19), 3012-3014, 2016 | 301 | 2016 |
| Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialPembrolizumab in … R Uppaluri, KM Campbell, AM Egloff, P Zolkind, ZL Skidmore, ... Clinical Cancer Research 26 (19), 5140-5152, 2020 | 283 | 2020 |
| Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited A Ribas, R Sengupta, T Locke, SK Zaidi, KM Campbell, JM Carethers, ... Cancer discovery 11 (2), 233-236, 2021 | 208 | 2021 |
| Best practices for bioinformatic characterization of neoantigens for clinical utility MM Richters, H Xia, KM Campbell, WE Gillanders, OL Griffith, M Griffith Genome medicine 11 (1), 1-21, 2019 | 192 | 2019 |
| Non-viral precision T cell receptor replacement for personalized cell therapy SP Foy, K Jacoby, DA Bota, T Hunter, Z Pan, E Stawiski, Y Ma, W Lu, ... Nature 615 (7953), 687-696, 2023 | 182 | 2023 |
| The prognostic effects of somatic mutations in ER-positive breast cancer OL Griffith, NC Spies, M Anurag, M Griffith, J Luo, D Tu, B Yeo, J Kunisaki, ... Nature communications 9 (1), 3476, 2018 | 141 | 2018 |
| Overcoming genetically based resistance mechanisms to PD-1 blockade DY Torrejon, G Abril-Rodriguez, AS Champhekar, J Tsoi, KM Campbell, ... Cancer discovery 10 (8), 1140-1157, 2020 | 128 | 2020 |
| Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma A Ribas, T Medina, JM Kirkwood, Y Zakharia, R Gonzalez, D Davar, ... Cancer Discovery 11 (12), 2998-3007, 2021 | 119 | 2021 |
| Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma A Kalbasi, M Tariveranmoshabad, K Hakimi, S Kremer, KM Campbell, ... Science translational medicine 12 (565), eabb0152, 2020 | 111 | 2020 |
| Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples EK Barnell, P Ronning, KM Campbell, K Krysiak, BJ Ainscough, LM Sheta, ... Genetics in Medicine 21 (4), 972-981, 2019 | 92 | 2019 |
| A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data BJ Ainscough, EK Barnell, P Ronning, KM Campbell, AH Wagner, ... Nature genetics 50 (12), 1735-1743, 2018 | 86 | 2018 |
| Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer KC Cotto, YY Feng, A Ramu, M Richters, SL Freshour, ZL Skidmore, H Xia, ... Nature communications 14 (1), 1589, 2023 | 78 | 2023 |
| Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial A VanderWalde, SL Bellasea, KL Kendra, NI Khushalani, KM Campbell, ... Nature medicine 29 (9), 2278-2285, 2023 | 77 | 2023 |
| PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma A Ribas, A Algazi, PA Ascierto, MO Butler, S Chandra, M Gordon, ... Nature communications 11 (1), 6262, 2020 | 71 | 2020 |
| Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia M Griffith, OL Griffith, K Krysiak, ZL Skidmore, MJ Christopher, JM Klco, ... Experimental hematology 44 (7), 603-613, 2016 | 56 | 2016 |
| Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles KM Campbell, G Steiner, DK Wells, A Ribas, A Kalbasi BioRxiv, 2020.03. 30.016931, 2020 | 51 | 2020 |
Obi L. GriffithAssociate Professor, Washington University School of MedicineПідтверджена електронна адреса в wustl.edu
